{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mae H"],"funding":["MEXT | Japan Society for the Promotion of Science","Osaka Medical Research Foundation for Intractable Diseases"],"pagination":["1152-1165"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10317042"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["3(7)"],"pubmed_abstract":["Clear cell sarcoma (CCS), a rare but extremely aggressive malignancy with no effective therapy, is characterized by the expression of the oncogenic driver fusion gene <i>EWSR1::ATF1</i>. In this study, we performed a high-throughput drug screening, finding that the histone deacetylase inhibitor vorinostat exerted an antiproliferation effect with the reduced expression of <i>EWSR1::ATF1</i>. We expected the reduced expression of <i>EWSR1::ATF1</i> to be due to the alteration of chromatin accessibility; however, assay for transposase-accessible chromatin using sequencing and a cleavage under targets and release using nuclease assay revealed that chromatin structure was only slightly altered, despite histone deacetylation at the EWSR1::ATF1 promoter region. Alternatively, we found that vorino"],"journal":["Cancer research communications"],"pubmed_title":["Targeting the Clear Cell Sarcoma Oncogenic Driver Fusion Gene <i>EWSR1::ATF1</i> by HDAC Inhibition."],"pmcid":["PMC10317042"],"funding_grant_id":["JP22K09375","JP22K16766","JP19K18481","JP19K18498"],"pubmed_authors":["Mae H","Outani H","Imura Y","Yasuda N","Inoue A","Nakai T","Takenaka S","Chijimatsu R","Kotani Y","Okada S","Nakai S"],"additional_accession":[]},"is_claimable":false,"name":"Targeting the Clear Cell Sarcoma Oncogenic Driver Fusion Gene <i>EWSR1::ATF1</i> by HDAC Inhibition.","description":"Clear cell sarcoma (CCS), a rare but extremely aggressive malignancy with no effective therapy, is characterized by the expression of the oncogenic driver fusion gene <i>EWSR1::ATF1</i>. In this study, we performed a high-throughput drug screening, finding that the histone deacetylase inhibitor vorinostat exerted an antiproliferation effect with the reduced expression of <i>EWSR1::ATF1</i>. We expected the reduced expression of <i>EWSR1::ATF1</i> to be due to the alteration of chromatin accessibility; however, assay for transposase-accessible chromatin using sequencing and a cleavage under targets and release using nuclease assay revealed that chromatin structure was only slightly altered, despite histone deacetylation at the EWSR1::ATF1 promoter region. Alternatively, we found that vorino","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jul","modification":"2026-05-29T09:06:11.574Z","creation":"2025-02-19T03:21:21.614Z"},"accession":"S-EPMC10317042","cross_references":{"pubmed":["37405123"],"doi":["10.1158/2767-9764.CRC-22-0518"]}}